TAP2 and neoplasm: There are two possibilities to diminish antigen presentation: (1) on the gene expression levels by DNA and/or histone methylation, as well as histone deacetylation, resulting in the low expression of self and tumor antigens (neoantigens and CTAs); (2) on the MHC class I levels (antigen-presenting machinery) by the epigenetic silencing of the genes involved in the antigen-presenting machinery, such as B2M, TAP1, and TAP2 [342,343].